Previous 10 | Next 10 |
With current HLHS treatment, only 50-60% of infants survive to adolescence In ELPIS I Phase 1 clinical trial, children experienced 100% transplant-free survival up to five years of age after receiving Lomecel-B™ compared to approximate 20% mortality rate observed from historical c...
Longeveron (NASDAQ: LGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions. The company today announced the launch of its contract development and manufacturing business at its 15,000-square-fo...
2024-06-03 09:33:10 ET More on Longeveron Longeveron Inc. (LGVN) Q1 2024 Earnings Call Transcript Longeveron announces board transitions Longeveron stock rallies 85% on Alzheimer's presentation (update) Seeking Alpha’s Quant Rating on Longeveron ...
Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues First manufacturing services contract signed with Secretome Therapeutics MIAMI, June 03, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a cl...
Longeveron (NASDAQ: LGVN) , a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, will be represented at next month’s 2024 BIO International Convention; the convention is scheduled to take plac...
MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the Company will participate in the BIO Internat...
2024-05-17 23:08:05 ET Longeveron Inc. (LGVN) Q1 2024 Earnings Conference Call May 14, 2024, 05:00 PM ET Company Participants Derek Cole - IR, Advisory Solutions Wa'el Hashad - CEO Nataliya Agafonova - Chief Medical Officer Lisa Locklear - CFO Joshua Hare...
2024-05-15 08:31:48 ET More on Longeveron Longeveron announces board transitions Longeveron stock rallies 85% on Alzheimer's presentation (update) Seeking Alpha’s Quant Rating on Longeveron Historical earnings data for Longeveron Read the ful...
Phase 2b clinical trial evaluating Lomecel-B TM in rare pediatric disease HLHS on track for completing enrollment by end of 2024 Data from Phase 2a clinical trial evaluating Lomecel-B TM in Alzheimer’s Disease selected for Featured Research Oral Presentation at 2024 Alzheimer...
Longeveron (NASDAQ: LGVN) , a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, is reporting changes on its board of directors. The following transitions on the board have been announced: Richard Kender, retired SVP of bu...
News, Short Squeeze, Breakout and More Instantly...
Longeveron (NASDAQ: LGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions. Longeveron presented at the Virtual Life Sciences Investor Forum on June 20. The company’s presentation ...
NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20 th are now available for online viewing. REGISTER NOW AT : ...